tiprankstipranks
Advertisement
Advertisement

EYPT Stock Latest News

EyePoint Pharmaceuticals Settles DEXYCU Case, Enhances Compliance Oversight
Company AnnouncementsEyePoint Pharmaceuticals Settles DEXYCU Case, Enhances Compliance Oversight
20h ago
8K
EYPT
EyePoint to pay $4.6M to resolve False Claim Act allegations
PremiumThe Fly
EyePoint to pay $4.6M to resolve False Claim Act allegations
1d ago
EYPT
EyePoint initiated with a Buy at Stifel
PremiumThe Fly
EyePoint initiated with a Buy at Stifel
3d ago
EYPT
EyePoint appoints Tarek Hassan as chief strategic science officer
PremiumThe Fly
EyePoint appoints Tarek Hassan as chief strategic science officer
5d ago
EYPT
EyePoint assumed with an Overweight at Cantor Fitzgerald
PremiumThe Fly
EyePoint assumed with an Overweight at Cantor Fitzgerald
10d ago
EYPT
Duravyu Pivotal Readout and Strong TKI Outlook Support Buy Rating; $43 Price Target Reiterated
PremiumRatingsDuravyu Pivotal Readout and Strong TKI Outlook Support Buy Rating; $43 Price Target Reiterated
12d ago
EYPT
EyePoint price target raised to $65 from $29 at Chardan
Premium
The Fly
EyePoint price target raised to $65 from $29 at Chardan
17d ago
EYPT
EyePoint Stockholders Approve Incentive Plan and Board Slate
Premium
Company Announcements
EyePoint Stockholders Approve Incentive Plan and Board Slate
26d ago
8K
EYPT
Analyst Reiterates Buy on EyePoint, Sees Durability as Key Differentiator with Price Target Maintained at $43
PremiumRatings
Analyst Reiterates Buy on EyePoint, Sees Durability as Key Differentiator with Price Target Maintained at $43
1M ago
EYPT
EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease
PremiumCompany Announcements
EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease
2M ago
EYPT
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
PremiumCompany Announcements
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
2M ago
EYPT
EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
PremiumThe Fly
EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
2M ago
EYPT
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
PremiumCompany AnnouncementsEyePoint Advances DURAVYU Phase 3 Wet AMD Program
2M ago
8K
EYPT
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
Premium
Company Announcements
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
2M ago
EYPT
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
Premium
Ratings
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
2M ago
EYPT
EyePoint reports Q1 EPS (99c), consensus (81c)
PremiumThe Fly
EyePoint reports Q1 EPS (99c), consensus (81c)
2M ago
EYPT
EYPT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
EYPT Upcoming Earnings Report: What to Expect?
3M ago
EYPT
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
PremiumWeekend Updates
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
3M ago
AGX
EYPT
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
PremiumCompany Announcements
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
3M ago
8K
EYPT
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
PremiumCompany AnnouncementsEyePoint Sues Ocular Therapeutix Over Alleged Defamation
4M ago
8K
EYPT
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
Premium
Company Announcements
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
4M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
Premium
The Fly
EyePoint reports inducement grants under NASDAQ listing rule
4M ago
EYPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >